Skip to main content
SpringerLink
Log in

Pharmakokinetik und Arzneimittelinteraktionen

  • Chapter
  • First Online:
Kompendium der Psychiatrischen Pharmakotherapie

  • 7969 Accesses

Zusammenfassung

Hintergründe zur Pharmakokinetik und zu Interaktionen werden dargestellt. Alle in der Psychopharmakotherapie relevanten Wechselwirkungen werden in Anhang INT und Anhang SUB ausführlich so aufgeführt, dass der Leser die einzelnen Risiken selbst nachvollziehen kann. Der Bezug zu den Angaben bei den einzelnen Präparaten wird hergestellt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Barski OA, Tipparaju SM, Bhatnagar A (2016) The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 40:553–624

    Article  Google Scholar 

  • Belmonte C, Ochoa D, Román M et al (2018) Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 polymorphisms on pharmacokinetics and safety of aripiprazole in healthy volunteers. Basic Clin Pharmacol Toxicol 122(6):596–605

    Article  CAS  Google Scholar 

  • Böhmdorfer B, Rohleder S, Wawruch M et al (2016) DEL-FINE: a new tool for assessing the delirogenic properties of drugs of relevance for European pharmacotherapy. Z Gerontol Geriatr 49(5):416–422

    Article  Google Scholar 

  • Elmeliegy M, Vourvahis M, Guo C, Wang DD (2020) Effect of P-glycoprotein (P-gp) Inducers on exposure of P-gp substrates: review of clinical drug-drug interaction studies. Clin Pharmacokinet 59(6):699–714

    Article  CAS  Google Scholar 

  • Haen E (2014) Arzneimittelinteraktionen. Nervenarzt 85:417–426

    Article  CAS  Google Scholar 

  • Herbild L, Andersen SE, Werge T et al (2013) Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs? Basic Clin Pharmacol Toxicol 113(4):266–272

    Article  CAS  Google Scholar 

  • Hicks JK, Swen JJ, Thorn CF et al (2013) Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 93:402–408

    Article  CAS  Google Scholar 

  • Hicks JK, Bishop JR, Sangkuhl K et al; Clinical Pharmacogenetics Implementation Consortium (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther 98:127–134

    Article  Google Scholar 

  • Hiemke C (2019) Concentration-effect relationships of psychoactive drugs and the problem to calculate therapeutic reference ranges. Ther Drug Monit 41(2):174–179

    Article  Google Scholar 

  • Hiemke C, Eckermann G (2014) Kombinationstherapie/Polypharmazie: Interaktionen von Psychopharmaka. Psychopharmakotherapie 21:269–279

    Google Scholar 

  • Hiemke C, Bergemann N, Clement HW et al (2018) Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 51:9–62

    Article  CAS  Google Scholar 

  • Jukić MM, Haslemo T, Molden E et al (2018) Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients. Am J Psychiatry 175:463–470

    Article  Google Scholar 

  • Koehn LM (2020) ABC efflux transporters at blood-central nervous system barriers and their implications for treating spinal cord disorders. Neural Regen Res 15(7):1235–1242

    Article  Google Scholar 

  • Koonrungsesomboon N, Khatsri R, Wongchompoo P, Teekachunhatean S (2018) The impact of genetic polymorphisms on CYP1A2 activity in humans: a systematic review and meta-analysis. Pharmacogenomics J 18(6):760–768

    Article  CAS  Google Scholar 

  • Manikandan P, Nagini S (2018) Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets 19(1):38–54

    Article  CAS  Google Scholar 

  • Nicolussi S, Drewe J, Butterweck V, Meyer Zu Schwabedissen HE (2020) Clinical relevance of St. John’s wort drug interactions revisited. Br J Pharmacol 177(6):1212–1226

    Article  CAS  Google Scholar 

  • Oda S, Fukami T, Yokoi T et al (2015) A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metab Pharmacokinet 30:30–51

    Article  CAS  Google Scholar 

  • Ostad Haji E, Tadic A, Wagner S et al (2013) Early improvement and serum concentrations of citalopram to predict antidepressant drug response of patients with major depression. Pharmacopsychiatry 46:261–266

    Article  CAS  Google Scholar 

  • Piel M, Schmitt U, Bausbacher N et al (2014) Evaluation of P-glycoprotein (abcb1a/b) modulation of [(18)F]fallypride in MicroPET imaging studies. Neuropharmacology 84:152–158

    Article  CAS  Google Scholar 

  • Relling MV, Klein TE, Gammal RS et al (2020) The clinical pharmacogenetics implementation consortium: 10 years later. Clin Pharmacol Ther 107(1):171–175

    Article  Google Scholar 

  • Saiz-Rodríguez M, Belmonte C, Román M et al (2018) Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants. Basic Clin Pharmacol Toxicol 123(4):474–485

    Article  Google Scholar 

  • Schoretsanitis G, Kane JM, Correll CU et al (2020) Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry 81(3):19cs13169

    Article  Google Scholar 

  • Scotton WJ, Hill LJ, Williams AC, Barnes NM (2019) Serotonin ayndrome: pathophysiology, clinical features, management, and potential future directions. Int J Tryptophan Res 12:1178646919873925

    Article  Google Scholar 

  • Unterecker S, Hefner G, Baumann P et al (2019) Therapeutisches Drug-Monitoring in der Neuropsychopharmakologie: Zusammenfassung der Konsensusleitlinien 2017 der TDM-Arbeitsgruppe der AGNP. Nervenarzt 90(5):463–471

    Article  Google Scholar 

  • van der Schans J, Hak E, Postma M et al (2019) Effects of pharmacogenetic screening for CYP2D6 among elderly starting therapy with nortriptyline or venlafaxine: a pragmatic randomized controlled trial (CYSCE Trial). J Clin Psychopharmacol 39(6):583–590

    Article  Google Scholar 

  • van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M, Jukić MM (2020) Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going? Front Psychiatry 11:94

    Article  Google Scholar 

  • Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–141

    Article  CAS  Google Scholar 

  • Zhou Y, Ingelman-Sundberg M, Lauschke VM (2017) Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther 102(4):688–700

    Article  CAS  Google Scholar 

  • Zubenko GS, Sommer BR, Cohen BM (2018) On the marketing and use of pharmacogenetic tests for psychiatric treatment. JAMA Psychiatry 75(8):769–770

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mainz, Deutschland

    Prof. Dr. rer. nat. Christoph Hiemke

  2. Mainz, Deutschland

    Otto Benkert

Authors
  1. Prof. Dr. rer. nat. Christoph Hiemke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Otto Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Otto Benkert .

Editor information

Editors and Affiliations

  1. ehemals Universitäts-Klinikum Mainz, Mainz, Germany

    Otto Benkert

  2. Klinik für Psychiatrie und Psychotherapie, ehemals Universitäts-Klinikum München Campus Innenstadt, München, Germany

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hiemke, C., Benkert, O. (2021). Pharmakokinetik und Arzneimittelinteraktionen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-61753-3_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-61753-3_16

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-61752-6

  • Online ISBN: 978-3-662-61753-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation